Table 2.
Meta-regression of covariates on prevalence of SAO
| Coefficient (% change in prevalence) | 95% CI | p value | |
|---|---|---|---|
| Spirometry parameter | |||
| FEF25–75 | (Ref) | – | – |
| FEF25–75/VC | − 14.3 | − 38.6, 10.0 | 0.250 |
| FEF50/FEF25 | 9.7 | 5.9, 13.4 | < 0.001 |
| FEV3/FVC | − 5.7 | − 9.3, − 2.1 | 0.002 |
| FEF50 | − 19.3 | − 23.1, − 15.6 | < 0.001 |
| WHO region | |||
| Americas | (ref) | – | – |
| European | 24.3 | 3.0, 45.6 | 0.025 |
| Western Pacific | 5.3 | 3.0, 7.5 | < 0.001 |
| South East Asia | 4.1 | − 18.7, 26.9 | 0.726 |
p < 0.05 = significant. FEF25–75: Mean expiratory flow rate between 25 and 75% of the FVC, FEF25–75/VC: Mean expiratory flow rate between 25 and 75% of the FVC as a ratio of the vital capacity. FEF50: Forced expiratory flow rate at 50% of the FVC. FEF50/FEF25: Forced expiratory flow at 50% of the FVC as a ratio or the forced expiratory flow with 25% of the FVC remaining, FEV3/FVC: forced expiratory volume in 3 s as a ratio of the FVC